- Stocks
- Healthcare
- NASDAQ: ALXN

Price (delayed)

$102.97

Market cap

$22.57B

P/E Ratio

27.31

Dividend/share

N/A

EPS

$3.77

Enterprise value

$22.35B

ALXN's revenue is up by 23% year-on-year and by 4.6% since the previous quarter

The company's gross profit rose by 23% YoY and by 4% QoQ

ALXN's price to earnings (P/E) is 73% lower than its 5-year quarterly average of 100.4 but 73% higher than its last 4 quarters average of 15.8

Alexion Pharmaceuticals's equity has decreased by 11% from the previous quarter but it has increased by 3.2% YoY

The EPS has dropped by 65% since the previous quarter and by 37% year-on-year

ALXN's net income has dropped by 64% since the previous quarter and by 37% year-on-year

What are the main financial stats of ALXN

Market
Valuations
Earnings

Shares outstanding

219.17M

Market cap

$22.57B

Enterprise value

$22.35B

Price to earnings (P/E)

27.31

Price to book (P/B)

2.17

Price to sales (P/S)

4.1

EV/EBIT

41.54

EV/EBITDA

24.83

EV/Sales

4.04

Revenue

$5.54B

EBIT

$538M

EBITDA

$900.2M

Free cash flow

$2.37B

Per share
Balance sheet
Liquidity

EPS

$3.77

Free cash flow per share

$10.72

Book value per share

$47.51

Revenue per share

$25.1

TBVPS

$43.37

Total assets

$16.7B

Total liabilities

$6.21B

Debt

$2.61B

Equity

$10.49B

Working capital

$4.25B

Debt to equity

0.25

Current ratio

4.79

Quick ratio

3.77

Net debt/EBITDA

-0.24

Margins
Efficiency
Dividend

EBITDA margin

16.3%

Gross margin

91.6%

Net margin

15.3%

Operating margin

8.2%

Return on assets

5%

Return on equity

7.7%

Return on invested capital

7.2%

Return on capital employed

3.5%

Return on sales

9.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Alexion Pharmaceuticals stock price performed over time

How have Alexion Pharmaceuticals's revenue and profit performed over time

Revenue

$5.54B

Gross profit

$5.07B

Operating income

$452.1M

Net income

$846.1M

Gross margin

91.6%

Net margin

15.3%

ALXN's operating margin has dropped by 82% since the previous quarter and by 75% year-on-year

The operating income has plunged by 81% from the previous quarter and by 70% YoY

The net margin has shrunk by 66% QoQ and by 48% YoY

ALXN's net income has dropped by 64% since the previous quarter and by 37% year-on-year

What is Alexion Pharmaceuticals stock price valuation

P/E

27.31

P/B

2.17

P/S

4.1

EV/EBIT

41.54

EV/EBITDA

24.83

EV/Sales

4.04

ALXN's price to earnings (P/E) is 73% lower than its 5-year quarterly average of 100.4 but 73% higher than its last 4 quarters average of 15.8

The EPS has dropped by 65% since the previous quarter and by 37% year-on-year

ALXN's P/B is 30% below its 5-year quarterly average of 3.1 but 3.3% above its last 4 quarters average of 2.1

Alexion Pharmaceuticals's equity has decreased by 11% from the previous quarter but it has increased by 3.2% YoY

ALXN's P/S is 49% below its 5-year quarterly average of 8.0 and 7% below its last 4 quarters average of 4.4

ALXN's revenue is up by 23% year-on-year and by 4.6% since the previous quarter

How efficient is Alexion Pharmaceuticals business performance

Alexion Pharmaceuticals's return on invested capital has shrunk by 79% QoQ and by 71% YoY

The ROS has dropped by 78% since the previous quarter and by 70% year-on-year

Alexion Pharmaceuticals's ROA has plunged by 66% from the previous quarter and by 47% YoY

Alexion Pharmaceuticals's ROE has plunged by 65% from the previous quarter and by 45% YoY

What is ALXN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ALXN.

How did Alexion Pharmaceuticals financials performed over time

ALXN's total assets is 169% higher than its total liabilities

ALXN's total liabilities is up by 41% year-on-year but it is down by 2.9% since the previous quarter

The company's quick ratio rose by 21% YoY and by 14% QoQ

The debt is 75% lower than the equity

Alexion Pharmaceuticals's debt to equity has increased by 14% from the previous quarter but it has decreased by 7% YoY

Alexion Pharmaceuticals's equity has decreased by 11% from the previous quarter but it has increased by 3.2% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.